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Development of germ cells is a process starting in fetus and completed only in puberty. Spermatogonial stem cells maintain
spermatogenesis throughout the reproductive life of mammals. They are undiﬀerentiated cells deﬁned by their ability to both self-
renewanddiﬀerentiateintomaturespermatozoa.Thisself-renewalanddiﬀerentiationinturnistightlyregulatedbyacombination
of intrinsic gene expression as well as the extrinsic gene signals from the local tissue microenvironment. The human testis is prone
to damage, either for therapeutic reasons or because of toxic agents from the environment. For preservation of fertility, patients
who will undergo radiotherapy and/or chemotherapy have an attractive possibility to keep in store and afterwards make a transfer
of spermatogonial stem cells. Germ cell transplantation is not yet ready for the human fertility clinic, but it may be reasonable
for young cancer patients, with no other options to preserve their fertility. Whereas this technique has become an important
research tool in rodents, a clinical application must still be regarded as experimental, and many aspects of the procedure need to
be optimized prior to a clinical application in men. In future, a range of options for the preservation of male fertility will get a new
signiﬁcance.
1.Introduction
In the normal human testis there are few cells, which are
important for such a multistaged process as spermatoge-
nesis. The most important cells are germ cells in their
various developmental stages, supporting Sertoli cells in the
seminiferous tubules, and interstitial Leydig cells producing
hormone testosterone, which is necessary for normal process
of spermatogenesis.
Normally, primordial germ cells diﬀerentiate into gono-
cytes, which transform to fetal spermatogonia from 10 to
22 weeks post conception. Fetal spermatogonia begin to
transform into adult dark (Adark) spermatogonia. Diploid
spermatogonial stem cells (SSCs) or type Adark spermato-
gonia have characteristic adult stem cell properties of self-
renewal and diﬀerentiation. Through assymetric cell divi-
sion, they replace themselves and produce more diﬀeren-
tiated progenitor daughter cells, also known as adult pale
(Apale) spermatogonia. Although both (Adark and Apale)a r e
commonly referred to as spermatogonial stem cells, their
biological functions are very diﬀerent and the Adark shows
characteristics indicating that it acts as a testicular stem cells.
The progeny of Apale are B spermatogonia. They proliferate
and diﬀerentiate to form four spermatocytes. Meiosis ensues
to produce haploid spermatids. It takes about 64 days
after a single SSC division, which gives rise to 16 haploid
spermatids before mature spermatozoa are formed [1]. The
spermatozoa are released into the lumen of seminiferous
tubules and are transported to the epididymis where they
continue to mature. Final steps of spermatogenesis occur
at puberty. During this period, the Sertoli cells develope,
and their total number decreases constantly from birth to
puberty. The mutual interaction between germ cells and
Sertoli cells plays a crucial role in their diﬀerentiation. The
cytokines produced by Sertoli cells regulate spermatogonial
and spermatocyte development, junctional integrity, and the
function of immunoregulatory cells present in interstitium
[2]. Leydig cells degenerate to minimal numbers by the age
of two years. At puberty, they diﬀerentiate to adult Leydig2 The Scientiﬁc World Journal
cells [3]. Peritubular myoid cells surround the seminiferous
tubules and express androgen receptors from fetal life to
adulthood. Recently, the molecular mechanisms of androgen
actionviathesecellsinspermatogenesishavebeenidentiﬁed,
which is essential for normal testis function [4], but, as
demonstrated by O’Shaughnessy and colleagues, androgen
stimulation of spermatogenesis, nevertheless, requires direct
androgen action on the Sertoli cells [5]. Identifying Colony
stimulating factor 1 (Csf1) as an extrinsic stimulator of
SSC self-renewal, it was implied that Leydig and peritubular
myoid cells are contributors of the testicular stem cell
niche in mammals [6]. As a plasma membrane component,
among other glycolipids in the mammalian testis, testis-
speciﬁc sulfoglycolipid, seminolipid, is essential for germ cell
function in spermatogenesis [7].
Induction of spermatogenesis depends on the comple-
mentary actions of follicle-stimulating hormone (FSH) and
androgens. FSH is capable to establish a suﬃcient Sertoli
cell population, while androgens (mostly testosterone) aﬀect
the functional completion of meiosis and postmeiotic sperm
diﬀerentiation and maturation. Luteinizing hormone (LH)
stimulates Leydig cell production of testosterone. FSH alone
can induce proliferation of Sertoli cells and spermatogonia
in the prepubertal primate, but this does not result in qual-
itatively and quantitatively normal spermatogenesis unless
testosterone is simultaneously present [8, 9]. Although FSH
appears to play a more prominent role in the maintenance
of primate spermatogenesis than in the initiation, normal
spermatogenesis is best maintained by the combined eﬀects
of FSH and LH [8]. As Plant and Marshall claimed, FSH
stimulationisprobablynotobligatoryforthemaintenanceof
spermatogenesis, but it is premature to infer that LH is suf-
ﬁcient and necessary [10]. Recently, Achard and colleagues
showed that complete and quantitatively normal spermato-
genesis may be triggerred and maintained by low levels of
luteinizing hormone activity postnatally and at puberty [11].
Stem cells are reserve cells capable of indeﬁnite self-
renewal. They have an extraordinary potential for therapeu-
tic use in regenerative medicine. Stem cells are controlled
by particular microenvironments known as niches. Male
germline stem cells, SSCs, have the capacity to continuosly
produce sperm during adult life, and they do it through
establishment of an SSCs population during early testis
development and its subsequent maintenance [12]. In recent
years, a few strategies have been introduced for preserving
fertility in prepubertal boys, adolescents, and adult men,
where it is necessary to apply anticancer therapy, or where
the infertility in man occurred for some other reasons.
All of these strategies include the application of SSCs in
the treatment of infertility. For these reasons, the aim of
this review was to make the connection between the SSCs
and main causes of male infertility, in which therapy they
could ﬁnd application, which refers to the treatment of
men of diﬀerent ages—prepubertal boys, adolescents, and
adult men (Figure 1). This is done through a review of
contemporary knowledge about these cells and some causes
of male infertility.
Stem cells Male infertility
SSCs Some forms of male infertility
Therapy
Prepubertal boys
Adolescents
Adult men
Figure 1: Possible therapeutic application of spermatogonial stem
cells (SSCs).
2. Male Infertilityand Causes
Infertility can be caused by defects in the development of
the urogenital system and in its function, by genetic defects
of the endocrine system, and by defects in gametogenesis,
erection, ejaculation, gamete function, fertilization, or early
embryonic development. Secondary or acquired infertility
can occur, among other causes, due to exposure to gonado-
toxins [13] .T h em o s tc o m m o nc a u s e so fm a l ei n f e r t i l i t y
include abnormal sperm production or function, impaired
deliver of sperm, and overexposure to certain gonadotoxins
from the environment. The pathogenesis of male infertility
can be attributed to the disorder of germ cell proliferation
and diﬀerentiation or to somatic cell dysfunction [14].
Among other causes, cryptorchid testes and testicular cancer
play an important role, as well as inﬂuence of radiotherapy
and/or chemotherapy used in the (other) cancer treatment.
Animal models, particularly knockout mouse models, and
their various applications are of great importance in studies
of male infertility [15].
Cryptorchidism is a common condition, with signiﬁcant
risks of infertility and malignancy. The mechanism of
normal testicular descent from an intraabdominal position
to an extraabdominal position (scrotum) occurs in two
basic steps. The ﬁrst step is transabdominal phase, when
testis is held close to the inguinal region. This phase is
triggered by hormonally controlled enlargement of the distal
gubernaculum. During the second, the inguinoscrotal phase,
the gubernaculum migrates across the pubic region into the
scrotum. This phase is indirectly controlled by androgens
via the genitofemoral nerve and release of neurotransmitters,
especially calcitonin gene-related peptide (CGRP) [16].
There are two forms of cryptorchidism: congenital (cryp-
torchidism A) and acquired (cryptorchidism B). Congenital
form is caused by any abnormality of the anatomical or
hormonal mechanisms. Unilateral undescended testis occurs
because androgens act independently on each side via
the ipsilateral genitofemoral nerve [17]. Acquired form is
caused by failure of postnatal elongation of the spermatic
cord, which, normally, should be doubled in length by
the 10th year [18]. The scrotal testis is cooler than inThe Scientiﬁc World Journal 3
the body cavity and is programmed to function at lower
temperature after birth. Hormon production and germ cell
development fail when the testis is located in the body
cavity, which leads to subsequent infertility and increased
risk of malignancy. Transformation from gonocyte to type
A spermatogonium is inhibited in these conditions [19].
But, when the cryptorchid testis is returned to the scrotum,
complete spermatogenesis is restored indicating that SSCs
remain functional [20]. Because diﬀerentiated germ cells are
absent in the cryptorchid testis, this testis cell population
might be expected to contain a greater concentration of stem
cells. Shinohara and colleagues showed in mouse models
that the total number of SSCs is approximately the same in
wild-type and cryptorchid testes, indicating that the elevated
temperature had little or no eﬀect on stem cells [21].
The human testis is an organ known for damage caused
by exposure to therapeutic agents and harmful factors from
the environment [22]. It has very active systems that work
together to regulate the extent of germ cell apoptosis.
Germ cells excessively proliferate, and physiological apop-
tosis optimizes their output to a satisfactory level for the
spermatogenesis. Uneven apoptosis can result in decreased
sperm output. After the exposure to a diﬀerent testicular
toxins,apoptosissigniﬁcantlyincreasesandleadstogermcell
damage and/or seminiferous epithelium becomes dysfunc-
tional [22]. Various agents are harmful to spermatogenesis
in diﬀerent animal models, and some of them are selective
for germ cells, some for Sertoli cells, while some aﬀect
the Leydig cells. In this way, spermatogenesis is suppressed
either by damage of germ cells, or by impossibility to create
microenvironment by Sertoli cells, or by lack of testosterone.
Chemotherapy with diﬀerent agents, like cysplatin, could
have profound eﬀects on spermatogenesis and various con-
secutive damages. In adult rats, there is a signiﬁcant reduc-
tionoftestosteroneinserumandtestessevendaysafterexpo-
sure to cisplatin. The germ cells die rapidly due to apoptosis
induced by cisplatin [23]. Spermatocytes are more sensitive
than spermatogonia to the eﬀects of cisplatin. It causes
long-lasting azoospermia and testicular atrophy in men.
Therefore, it is likely that cisplatin targets multiple cell types
and molecular pathways while producing testicular injury
[22].
3. Stem Cells Characteristics
Three main characteristics deﬁne stem cells: self-renew abil-
ity, the ability to diﬀerentiate into one or more lineages of
specialized cell types, and an enormous proliferative poten-
tial for the maintenance of the tissues they populate [24, 25].
The physiological role of a stem cell includes coordinated
control of growth and diﬀerentiation, as well as induction
of apoptosis, which distinguish them from malignant cancer
cells [26]. Stem cells allow blood, bone, gametes, epithelia,
nervous system, muscle, and many other tissues to be
replenished by fresh cells throughout life [27]. In most
systems,thestemcellsdonotderiveﬁnallydiﬀerentiatedcells
directlybutdosothroughprogenitorcells.Theseprogenitors
are intermediate cell populations inserted between stem and
diﬀerentiated cells. Thus, the stem cells play the role of a re-
generative reserve, and progenitor cells play the role of a
functionalreserve,producingexactlythenumberofdiﬀeren-
tiating cells needed for tissue homeostasis [1].
Stem cells are classiﬁed according to their developmental
potential as totipotent, pluripotent, multipotent, and unipo-
tent. A totipotent stem cell, zygote and its oﬀspring cells
of morula, can give rise to a new individual. A pluripotent
stem cell can give rise to all cell types of the embryo
proper, including somatic and germ cells. Adult stem cells
are multipotent if they are able to diﬀerentiate into multiple
cell types of a single tissue. Examples include haematopoietic
stem cells, mesenchymal stem cells, and neural stem cells.
They are isolated from the developing germ layers and/or
its descended adult organs [28]. The unipotent cells, or
precursor cells, exhibit limited or no capacity for self-
renewal and are able to contribute only to one mature cell
type.
Adult stem cells were ﬁrst described in tissues charac-
terized by a high rate of cell turnover, such as blood, skin,
gut, and testis. Recent reports claim that stem cells can be
even found in most adult organs that do not display high
rate of cell turnover [25]. Stem cells are controlled within
restricted tissue microenvironments known as “niches”. A
niche consists of a local tissue microenvironment capable
of housing and maintaining one or more stem cells. It
is localized and not a general tissue property. Niches
integrate local and systemic signals for the regulation and
maintenance for resident stem cells [27]. Two basic types of
niche have been recognized at the tips of adult Drosophila
female and male gonads. “Stromal cell” niches develop
whether or not stem cells are present and maintain their
morphology after stem cell loss. They have distinct “stromal”
cell types—cap cells and hub cells which are in direct
contact and signal to resident stem cells. The stromal cells
often secrete growth factors to regulate stem cell behavior
[29]. Stem cell niches have a diﬀerent conﬁguration in
various tissues. In addition to maintaining stem cells during
division, they must prevent external cells from gaining entry
and displacing the resident stem cells. The existence of
a mechanism for stem cell replacement might also have
deleterious eﬀects over the course of a long lifespan in tissue
with a large number of stem cells and niches. Mutations
within stem cells, that enhance the ability of daughter cells
to target and replace nearby stem cells, would tend to
increase their representation among the stem cells within
at i s s u e[ 30]. Also, the data from Drosophila germ line
stem cells show a phenomenon, which might also exist in
mammals, where two diﬀerent types of stem cells share
the same niche [31]. Singh and colleagues concluded that
Janus kinase/signal transducer and activator of transcription
(JAK/STAT) signaling controls competitiveness for the niche
and mutual dependence of SSCs and somatic cyst progenitor
cells [32]. Finally, it was established that pluripotent stem
cells can be directly generated from ﬁbroblast cultures
(reprogramming) by the addition of only a few deﬁned
factors. This ﬁnding may eventually allow the creation of
pluripotent cells directly from somatic cells of patients
[33–35].4 The Scientiﬁc World Journal
4. Spermatogonial Stem Cells
Spermatogonial stem cells (SSCs) are speciﬁc germ cells
that diﬀerentiate to initiate the process leading to the
formation of sperm [32]. They are undiﬀerentiated cells
deﬁned by their ability to both self-renew and diﬀerentiate
into mature spermatozoa. Although critically important for
the production of sperm, SSCs have been diﬃcult to study
because of their small number in the testis and challenges
associated with identifying, culturing, and assaying their
biological activity [36]. They may diﬀerentiate into various
types of somatic cells under speciﬁc conditions in vitro and
form teratomas after inoculation into mice [37].
SSCs or testicular stem cells originate from primordial
germ cells that travel to the gonadal ridges during embry-
onic development. After migration into the undiﬀerentiated
gonads, the primordial germ cells diﬀerentiate into female or
male germ cell precursor depending on the sexual gonadal
diﬀerentiation [38]. After the prepubertal initiation of germ
cell diﬀerentiation, spermatogenesis is maintained by the
ability of SSCs to provide a continual supply of diﬀerenti-
ating spermatogonia. SSCs have an ability to self-renew, to
create additional stem cells and cells destined for diﬀeren-
tiation. To maintain this ability, like other adult stem cells,
SSCs need to reside in a unique environment, or niche, that
provides the factors for their survival and potential. Ehmcke
andcolleaguesconcludedthatavarietyofdiﬀerenttotipotent
and germ line cells are capable to enter meiosis under in vitro
conditions but that male germ cell diﬀerentiation occurs
exclusively in the intact testicular microenvironment [39].
They claim, also, that the testicular microenvironment oﬀers
unique niches to germ cells. Physically, the SSC niche most
likely lies along the basement membrane of the seminiferous
tubule, with the Sertoli cells contributing to this microen-
vironment [36]. The Sertoli cells are specialized cells which
provide the nutritional and architectural support required
for adult germ cell development [12]. In mammals, the
somatic Sertoli cell is responsible for maintaining the SSC.
SertolicellscreateformationofSSCnichesthroughsecretion
of speciﬁc growth factors, and inducing output of secreted
factors from Leydig cells and other interstitial cell popula-
tions[40].Untilrecently,itwassuggestedthatasingleSertoli
cell factor, glial cell line-derived neurotropic factor (GDNF),
which is a protein member of the TGF-β superfamily, is most
likelyresponsibleforthat.Now,therearedatasuggestingthat
SSC regulation changes as the testis develops from perinatal
to pubertal age, the perinatal period is regulated by GDNF,
andthepubertalperiodisdependentonEts-relatedmolecule
(ERM). ERM is localized in the Sertoli cell, the only somatic
cell of the seminiferous epithelium, and it was established
that in adult testes Sertoli cells maintain the SSC niche. This
molecule is essential for stem cell renewal in pubertal and
adult testes [41]. The number of SSCs increases from birth
to sexual maturity, when the seminiferous tubule appears
to provide an environment supportive of the formation of
new niches. It was suggested that SSCs can develop new
niches during the initiation of spermatogenesis [34]. Also,
there is an evidence that SSCs exhibit diﬀerent phenotypes
in diﬀerent biological microenvironments [42].
In the testis, SSCs, residing in a niche, can regenerate
spermatogenesis even following a toxic insult [43]. In con-
trast, damage to the niche or Sertoli cell microenvironment
may limit or prevent SSC engraftment [12]. There is also
a signiﬁcant opportunity that the embryonic stem cells are
able in vitro to give rise to SSCs that can produce functional
g a m e t e sw h i c ha r ea b l et of e r t i l i z eo o c y t e s[ 44].
Nowadays, there are two crucial questions for a more
complete elucidation of the role of SSCs: what is the signal
that stimulates an SSC to begin the process of diﬀerentiation,
and whatis the signal that stimulates an SSC to divide to self-
renew the SSCs population [45].
5. Spermatogonial Stem Cells in the
Treatment of Infertility
Grafting of isolated testis cells has been developed more
recently, and as such it has been explored less than tissue
xenografting. There is the remarkable capability of isolated
postnatal testis cells to recapitulate testis development and
undergo complete diﬀerentiation [46]. SSCs are unique
among the adult stem cells because they are the only self-
renewing population of cells that genetically contribute to
the next generation [43]. Infertility after testicular exposure
to moderate doses of radiation and some chemotherapeutic
agents occurs as a result of inability of spermatogonia to
diﬀerentiate. After cytotoxic therapies, germ cells appear to
be absent, and the tubules contain only Sertoli cells. This
could be a result of killing the SSCs, the loss of ability
of the Sertoli cells to support the diﬀerentiation of SSCs,
or both [47]. In those patients whose anticancer therapy
clinically predicts a complete depletion of SSCs, the outlined
approaches of germ cell transplantation and testicular graft-
ingmightoﬀeroptions forfertilitypreservation.Atechnique
for transplanting SSCs was ﬁrst described by Brinster and
colleagues [48, 49]. Restoration of fertility following SSCs
transplantation in rodents suggests therapeutic potential for
the technique in humans. Further research is necessary,
especially in primate models, and the cryopreservation of
testicular cells and/or tissue should be considered an signif-
icant aspect of oncological therapy [50]. For preservation of
fertility, an attractive proposition is the storage and transfer
of SSCs. The gonocytes can be frozen-stored prior to transfer
and still produce fertile seminiferous tubules. When SSCs
are harvested from donor testes and transplanted into a
sterilized recipient testis, morphologically and functionally
normal spermatogenesis is reestablished [13]. Rat gonocytes
produced mature spermatozoa in testes of immunodeﬁ-
cient mice [51]. They were able to fertilize oocytes by in
vivo fertilization (IVF) but with reduced fertilization and
development rates in the transplanted group, where live
born pups did not show anomalies, but one was observed
with a lower pregnancy rate and a smaller litter size in
females impregnated with transplanted male mice [52].
This diﬀerence may be due to the lower motility in the
epididymal sperm of transplanted animals [53]. Also, the
testis appears tolerant to foreign cells, especially because of
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this barrier. The blood-testis barrier maintains a selective
ﬂow between luminal ﬂuid, interstitial ﬂuid, and plasma,
creating an immune-privileged environment for germ cells
[54]. The number and quality of semen specimens is often
unsatisfactory, deteriorating further with cryopreservation,
and it is not an option for prepubertal boys [55].
Currently, male cancer patients, prior to receiving ster-
ilizing doses of chemotherapy and/or radiotherapy, may be
oﬀered semen cryopreservation followed by thawing and
insemination. For preservation of fertility, autographs avoid
both the immunological problems of allografts and the
ethical dilemma when using donor tissue. The banking of
at least three semen samples with an abstinence of at least
48 hours between samples is good choice, and it has been
recommended [56]. Adolescents and adult men have the
option of cryobanking their semen before cancer treatment
and, by IVF or intracytoplasmic sperm injection (ICSI), they
can become fathers of children who are genetically their
own. In contrast, prepubertal boys cannot beneﬁt from this
approach since they do not have completed spermatogenesis,
because their seminiferous epithelium contains only Sertoli
cells and diﬀerent types of spermatogonia, among which are
the SSCs [57]. But, it is possible to develop the successful
transplantationofSSCsandLeydigcellprogenitors,conserv-
ing the fertility of juvenile patients undergoing radiotherapy
during cancer treatment [43, 58]. A necessary step in saving
the fertility of young male human cancer patients will be
by way of taking a biopsy before chemotherapy, propagation
of SSCs in culture, cryopreservation of the cells, and trans-
plantation back to the patients after a cure and after puberty
[59–62]. Testicular biopsy and tissue cryopreservation hold
promise for this young patients, but additional scientiﬁc
advances are still needed to translate successes in animal
research to human clinical practice, and the latest results
showtheattemptsofscientiststoachieveinvitropropagation
o fS S C si nh u m a n s[ 63, 64]. Preservation of testicular tissue
fromprepubertalpatientswillallowthemtoconsidervarious
fertility restoration options that will emerge in next two or
three decades, giving them hope of fathering children with
their own genetic heritage [65]. It was shown that immature
testicular tissue has a surprisingly high potential to survive
and diﬀerentiate as an auto- or xenograft [66].
It has already been proven that SSCs, present in testes of
patientswithnonobstructiveazoospermia,canbeisolateand
propagate in vitro using the highly eﬃcient culture system
and produce diﬀerentiating germ cells with developmental
potential [67]. Hence, it would be taken into account
that the testis biopsy taken from the cancer patient may
contain malignant cells. These cells should be removed
from the cell suspension because one single malignant
cell may reintroduce the disease [68]. Thus, application
of negative biomarkers for SSCs should allow depletion of
tumor cells from a testis biopsy, which assure protection
against tumor relapse [69]. Further, there is a need for the
preparation of recipient, which involves the destruction of
endogenous germ cells and blockade of spermatogenesis, to
allow transplanted SSCs to translocate from the lumen to
the basal compartment of the seminiferous tubule and begin
donor-derived spermatogenesis. Based on experiments on
mice, it is showed that potential safety hazards, associated
with busulfan or other cytotoxic treatments, can be avoided
by heat shock treatment (testicular hyperthermia), during
which spermatogonial niches stay maintained and capable of
supporting donor-derived spermatogenesis [70].
If chemotherapy and/or radiotherapy have already been
started, collection and cryopreservation of semen are still
feasible during treatment, at least until azoospermia ensues.
In these cases, the eﬀects of these gonadotoxic agents on
sperm are unknown. But, testicular sperm extraction is
possible from nonobstructive azoospermic cancer patients,
which in combination with ICSI gives a potential new
treatment option [56]. The studies revealed that diﬀerences
in the regulation of spermatogenesis do not allow the
xenodiﬀerentiation of germ cells, most likely because of
disturbed communication between nonrodent germ cells
and a mouse seminiferous epithelium [1]. Nowadays, it is
demonstrated that the organ culture conditions can support
the complete spermatogenesis of mice [71]. Also, it is not
known whether the oﬀspring, especially those produced
from cryopreserved tissue, are healthy in general, but fertility
of the oﬀspring is just a crude indicator of whether gametes
are “normal” or not [72].
6.Perspectives
Exciting research in SSCs transplantation oﬀers the potential
for future therapy to restore fertility in previously infertile
men. In the future, by performing experiments, mostly on
small mammals, there will be many new information on
using these germ cells for possible preservation of fertility.
For this purpose, spermatogonial and other types of stem
cells will be used. For example, adult bone marrow cells, in
a favorable testicular environment, diﬀerentiate into somatic
and germ cell lineages [13]. Further, the isolation of germ
line-competent cells from sources other than the testis may
render it possible to even use female cell preparation as
donor cell preparations for germ cell transplantation and
the reinitiation of spermatogenesis [1]. Also, by using better
protocols for cryopreservation and cryostorage, success of
fertilitypreservation,viatestistissueorSSCstransplantation,
will be mostly guaranteed. Finally, it should be noted that
SSCs may also oﬀer a renewable source of cells to be used
to correct many diseases of aging, to develop new cell-based
therapies, and to advance germline gene therapy [12].
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